Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 54 | 2023 | 104 | 9.770 |
Why?
|
| Graft vs Host Disease | 23 | 2023 | 53 | 3.870 |
Why?
|
| Leukemia, Myeloid, Acute | 16 | 2023 | 51 | 2.630 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 6 | 2023 | 33 | 1.370 |
Why?
|
| Transplantation Conditioning | 23 | 2023 | 38 | 1.300 |
Why?
|
| Transplantation, Homologous | 17 | 2023 | 198 | 0.870 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2022 | 31 | 0.860 |
Why?
|
| Hodgkin Disease | 5 | 2021 | 19 | 0.820 |
Why?
|
| Humans | 66 | 2023 | 23187 | 0.810 |
Why?
|
| Hematologic Neoplasms | 2 | 2020 | 19 | 0.750 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 13 | 0.700 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2023 | 32 | 0.640 |
Why?
|
| Recurrence | 13 | 2023 | 268 | 0.610 |
Why?
|
| Retrospective Studies | 24 | 2023 | 2993 | 0.590 |
Why?
|
| Eye Diseases | 4 | 2019 | 8 | 0.580 |
Why?
|
| Primary Myelofibrosis | 3 | 2023 | 3 | 0.560 |
Why?
|
| Middle Aged | 26 | 2023 | 7981 | 0.500 |
Why?
|
| Adult | 26 | 2023 | 6959 | 0.500 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 240 | 0.480 |
Why?
|
| Cyclophosphamide | 8 | 2023 | 44 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 202 | 0.470 |
Why?
|
| Prognosis | 12 | 2023 | 730 | 0.400 |
Why?
|
| Transplantation, Autologous | 7 | 2021 | 98 | 0.370 |
Why?
|
| Disease-Free Survival | 10 | 2022 | 171 | 0.370 |
Why?
|
| Adolescent | 12 | 2023 | 1884 | 0.360 |
Why?
|
| Aged | 20 | 2023 | 7660 | 0.350 |
Why?
|
| Male | 22 | 2022 | 12659 | 0.340 |
Why?
|
| Calcineurin Inhibitors | 5 | 2023 | 15 | 0.340 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 67 | 0.340 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 14 | 0.330 |
Why?
|
| Salvage Therapy | 2 | 2021 | 32 | 0.310 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2020 | 8 | 0.300 |
Why?
|
| Allografts | 5 | 2021 | 147 | 0.300 |
Why?
|
| Young Adult | 11 | 2021 | 1657 | 0.290 |
Why?
|
| Female | 21 | 2023 | 13142 | 0.280 |
Why?
|
| Survival Rate | 8 | 2021 | 320 | 0.260 |
Why?
|
| Hemoglobin SC Disease | 1 | 2006 | 1 | 0.240 |
Why?
|
| Splenic Diseases | 1 | 2006 | 2 | 0.240 |
Why?
|
| Rituximab | 3 | 2023 | 38 | 0.240 |
Why?
|
| Chromosome Aberrations | 3 | 2021 | 16 | 0.230 |
Why?
|
| Melphalan | 5 | 2023 | 5 | 0.220 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 113 | 0.210 |
Why?
|
| Risk Factors | 5 | 2023 | 2020 | 0.210 |
Why?
|
| Quality of Life | 4 | 2022 | 564 | 0.210 |
Why?
|
| Mycoses | 1 | 2023 | 17 | 0.200 |
Why?
|
| Scedosporium | 1 | 2023 | 2 | 0.200 |
Why?
|
| Bacterial Infections | 1 | 2023 | 47 | 0.200 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2023 | 2 | 0.190 |
Why?
|
| Myeloablative Agonists | 2 | 2020 | 2 | 0.190 |
Why?
|
| Remission Induction | 5 | 2022 | 89 | 0.190 |
Why?
|
| Unrelated Donors | 4 | 2023 | 5 | 0.180 |
Why?
|
| Bone Marrow | 4 | 2023 | 61 | 0.180 |
Why?
|
| Heart Failure | 1 | 2023 | 141 | 0.180 |
Why?
|
| Drug Resistance | 2 | 2019 | 45 | 0.180 |
Why?
|
| Vidarabine | 4 | 2023 | 8 | 0.180 |
Why?
|
| Autografts | 2 | 2019 | 20 | 0.180 |
Why?
|
| Hypogonadism | 1 | 2021 | 6 | 0.180 |
Why?
|
| Infertility | 1 | 2021 | 7 | 0.180 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 20 | 0.180 |
Why?
|
| Busulfan | 4 | 2023 | 4 | 0.180 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 18 | 0.180 |
Why?
|
| Bone Marrow Transplantation | 4 | 2023 | 19 | 0.170 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 15 | 0.170 |
Why?
|
| Roseolovirus Infections | 1 | 2021 | 3 | 0.170 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2021 | 5 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 18 | 0.170 |
Why?
|
| Siblings | 4 | 2022 | 14 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 1 | 2021 | 29 | 0.170 |
Why?
|
| Return to Work | 1 | 2021 | 38 | 0.170 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 36 | 0.170 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2020 | 2 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 10 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 295 | 0.160 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 4 | 0.160 |
Why?
|
| Calcineurin | 1 | 2020 | 8 | 0.160 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 2 | 0.160 |
Why?
|
| Infliximab | 1 | 2020 | 17 | 0.160 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2019 | 3 | 0.160 |
Why?
|
| Survival Analysis | 4 | 2021 | 226 | 0.150 |
Why?
|
| Neoplasms | 1 | 2022 | 218 | 0.150 |
Why?
|
| Transplantation, Haploidentical | 1 | 2019 | 1 | 0.150 |
Why?
|
| Steroids | 1 | 2019 | 21 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 163 | 0.150 |
Why?
|
| Typhlitis | 1 | 2019 | 2 | 0.150 |
Why?
|
| Mucositis | 1 | 2019 | 4 | 0.150 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 5 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 79 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 82 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 207 | 0.140 |
Why?
|
| Lung Diseases | 1 | 2019 | 36 | 0.140 |
Why?
|
| Incidence | 4 | 2023 | 633 | 0.140 |
Why?
|
| Liver Diseases | 1 | 2019 | 33 | 0.140 |
Why?
|
| Acute Disease | 3 | 2023 | 163 | 0.140 |
Why?
|
| Lymphoma | 1 | 2017 | 35 | 0.130 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 9 | 0.130 |
Why?
|
| Cachexia | 1 | 2017 | 10 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 369 | 0.130 |
Why?
|
| Child, Preschool | 3 | 2023 | 569 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2023 | 377 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2020 | 2943 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 3865 | 0.110 |
Why?
|
| Interleukin-2 | 1 | 2012 | 22 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2021 | 550 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 45 | 0.090 |
Why?
|
| Melanoma | 1 | 2012 | 49 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2022 | 1467 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 75 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 194 | 0.080 |
Why?
|
| Vincristine | 2 | 2023 | 23 | 0.080 |
Why?
|
| Tacrolimus | 2 | 2021 | 14 | 0.080 |
Why?
|
| Prednisone | 2 | 2023 | 64 | 0.080 |
Why?
|
| Doxorubicin | 2 | 2023 | 60 | 0.080 |
Why?
|
| Mutation | 2 | 2023 | 330 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 1430 | 0.080 |
Why?
|
| Leukocyte Count | 2 | 2020 | 58 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2020 | 1512 | 0.070 |
Why?
|
| Cytarabine | 2 | 2020 | 11 | 0.070 |
Why?
|
| Etoposide | 2 | 2020 | 27 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 288 | 0.070 |
Why?
|
| Registries | 2 | 2020 | 174 | 0.070 |
Why?
|
| Comorbidity | 2 | 2020 | 429 | 0.070 |
Why?
|
| Pain | 2 | 2021 | 332 | 0.070 |
Why?
|
| Disease Progression | 2 | 2022 | 547 | 0.070 |
Why?
|
| Child | 2 | 2021 | 1160 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 279 | 0.060 |
Why?
|
| United States | 2 | 2023 | 1803 | 0.060 |
Why?
|
| Erythropoiesis | 1 | 2006 | 1 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2006 | 6 | 0.060 |
Why?
|
| Splenectomy | 1 | 2006 | 6 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2006 | 6 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 50 | 0.060 |
Why?
|
| Fever | 1 | 2006 | 32 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 353 | 0.060 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2023 | 17 | 0.050 |
Why?
|
| Toes | 1 | 2023 | 3 | 0.050 |
Why?
|
| Voriconazole | 1 | 2023 | 10 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2023 | 67 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2023 | 35 | 0.050 |
Why?
|
| Whole-Body Irradiation | 1 | 2022 | 9 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 21 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2022 | 11 | 0.050 |
Why?
|
| Bortezomib | 1 | 2021 | 4 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 6 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 69 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 42 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 12 | 0.040 |
Why?
|
| Cell Count | 1 | 2020 | 72 | 0.040 |
Why?
|
| Lymphocyte Transfusion | 1 | 2020 | 1 | 0.040 |
Why?
|
| Carmustine | 1 | 2020 | 2 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 41 | 0.040 |
Why?
|
| Pyrazines | 1 | 2019 | 11 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 56 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 30 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2020 | 51 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 168 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 50 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 57 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 126 | 0.040 |
Why?
|
| Blood Donors | 1 | 2019 | 5 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 69 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2018 | 3 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 51 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 651 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2018 | 118 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 110 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 13 | 0.030 |
Why?
|
| Ifosfamide | 1 | 2017 | 13 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 162 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 18 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 26 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 230 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2017 | 34 | 0.030 |
Why?
|
| Methotrexate | 1 | 2017 | 36 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 486 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 122 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 313 | 0.020 |
Why?
|